{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T05:00:06Z","timestamp":1783832406798,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00393-024-01600-0","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T14:14:33Z","timestamp":1733408073000},"page":"338-344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of urate-lowering therapy on all-cause and CVD-specific mortality in gout and hyperuricemia: a\u00a0meta-analysis","Auswirkungen von harns\u00e4uresenkender Therapie auf die Gesamt- und die kardiovaskul\u00e4re Mortalit\u00e4t bei Gicht und Hyperurik\u00e4mie: eine Metaanalyse"],"prefix":"10.1007","volume":"83","author":[{"given":"Young Ho","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwan Gyu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"1600_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jare.2017.04.008","volume":"8","author":"G Ragab","year":"2017","unstructured":"Ragab\u00a0G, Elshahaly\u00a0M, Bardin\u00a0T (2017) Gout: an old disease in new perspective\u2014a review. J\u00a0Adv Res 8:495\u2013511","journal-title":"J Adv Res"},{"key":"1600_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4078\/jrd.2020.27.3.174","volume":"27","author":"JS Park","year":"2020","unstructured":"Park\u00a0JS, Kang\u00a0M, Song\u00a0J\u2011S, Lim\u00a0HS, Lee\u00a0CH (2020) Trends of gout prevalence in south korea based on medical utilization: a\u00a0national health insurance service database (2002\u223c2015). J\u00a0Rheum Dis 27:174\u2013181","journal-title":"J Rheum Dis"},{"key":"1600_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4078\/jrd.2022.29.3.140","volume":"29","author":"S-K Kim","year":"2022","unstructured":"Kim\u00a0S\u2011K (2022) The mechanism of the NLRP3 Inflammasome activation and pathogenic implication in the pathogenesis of gout. J\u00a0Rheum Dis 29:140\u2013153","journal-title":"J Rheum Dis"},{"key":"1600_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2008.02.024","volume":"392","author":"G Lippi","year":"2008","unstructured":"Lippi\u00a0G, Montagnana\u00a0M, Franchini\u00a0M, Favaloro\u00a0EJ, Targher\u00a0G (2008) The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta 392:1\u20137","journal-title":"Clin Chim Acta"},{"key":"1600_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4078\/jrd.2023.0011","volume":"30","author":"HJ Kim","year":"2023","unstructured":"Kim\u00a0HJ, Ghang\u00a0B, Kim\u00a0J, Ahn\u00a0HS (2023) Regional variations of cardiovascular risk in gout patients: a\u00a0nationwide cohort study in Korea. J\u00a0Rheum Dis 30:185\u2013197","journal-title":"J Rheum Dis"},{"key":"1600_CR6","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2174\/1381612825666190408122557","volume":"25","author":"S Zhang","year":"2019","unstructured":"Zhang\u00a0S, Wang\u00a0Y, Cheng\u00a0J, Huangfu\u00a0N, Zhao\u00a0R, Xu\u00a0Z, Zhang\u00a0F, Zheng\u00a0W, Zhang\u00a0D (2019) Hyperuricemia and cardiovascular disease. Curr Pharm Des 25:700\u2013709","journal-title":"Curr Pharm Des"},{"key":"1600_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fmed.2018.00160","volume":"5","author":"CL Benn","year":"2018","unstructured":"Benn\u00a0CL, Dua\u00a0P, Gurrell\u00a0R, Loudon\u00a0P, Pike\u00a0A, Storer\u00a0RI, Vangjeli\u00a0C (2018) Physiology of hyperuricemia and urate-lowering treatments. Front Med 5:160","journal-title":"Front Med"},{"key":"1600_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4078\/jrd.2023.0029","volume":"30","author":"JJ Lee","year":"2023","unstructured":"Lee\u00a0JJ, Lee\u00a0JS, Chung\u00a0MK et\u00a0al (2023) Korean guidelines for the management of gout. J\u00a0Rheum Dis 30:141\u2013150","journal-title":"J Rheum Dis"},{"key":"1600_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/14656566.2017.1349099","volume":"18","author":"R Soskind","year":"2017","unstructured":"Soskind\u00a0R, Abazia\u00a0DT, Bridgeman\u00a0MB (2017) Updates on the treatment of gout, including a\u00a0review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares. Expert Opin Pharmacother 18:1115\u20131125","journal-title":"Expert Opin Pharmacother"},{"key":"1600_CR10","doi-asserted-by":"crossref","unstructured":"Chen R, Nie S, Zhou S, Su L, Li Y, Zhang X, Luo F, Xu R, Gao Q, Lin Y (2024) Association between urate-lowering therapy initiation and all-cause mortality in patients with type\u00a02 diabetes and asymptomatic hyperuricemia. Diabetes Metab Syndr 103043:","DOI":"10.1016\/j.dsx.2024.103043"},{"key":"1600_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M21-2347","volume":"175","author":"J Wei","year":"2022","unstructured":"Wei\u00a0J, Choi\u00a0HK, Neogi\u00a0T, Dalbeth\u00a0N, Terkeltaub\u00a0R, Stamp\u00a0LK, Lyu\u00a0H, McCormick\u00a0N, Niu\u00a0J, Zeng\u00a0C (2022) Allopurinol initiation and all-cause mortality among patients with gout and concurrent chronic kidney disease: a\u00a0population-based cohort study. Ann Intern Med 175:461\u2013470","journal-title":"Ann Intern Med"},{"key":"1600_CR12","doi-asserted-by":"publisher","first-page":"e0234909","DOI":"10.1371\/journal.pone.0234909","volume":"15","author":"F-S Yen","year":"2020","unstructured":"Yen\u00a0F\u2011S, Hsu\u00a0C\u2011C, Li\u00a0H\u2011L, Wei\u00a0JC\u2011C, Hwu\u00a0C\u2011M (2020) Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout. Plos One 15:e234909","journal-title":"Plos One"},{"key":"1600_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.amjmed.2015.11.003","volume":"129","author":"KS Larsen","year":"2016","unstructured":"Larsen\u00a0KS, Potteg\u00e5rd\u00a0A, Lindegaard\u00a0HM, Hallas\u00a0J (2016) Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a\u00a0cohort study. Am J Med 129:299\u2013306. e292","journal-title":"Am J Med"},{"key":"1600_CR14","doi-asserted-by":"publisher","first-page":"e0145193","DOI":"10.1371\/journal.pone.0145193","volume":"10","author":"J-H Chen","year":"2015","unstructured":"Chen\u00a0J\u2011H, Lan\u00a0J\u2011L, Cheng\u00a0C\u2011F, Liang\u00a0W\u2011M, Lin\u00a0H\u2011Y, Tsay\u00a0GJ, Yeh\u00a0W\u2011T, Pan\u00a0W\u2011H (2015) Effect of urate-lowering therapy on all-cause and cardiovascular mortality in hyperuricemic patients without gout: a\u00a0case-matched cohort study. Plos One 10:e145193","journal-title":"Plos One"},{"key":"1600_CR15","first-page":"2145","volume":"54","author":"C-F Kuo","year":"2015","unstructured":"Kuo\u00a0C\u2011F, Grainge\u00a0MJ, Mallen\u00a0C, Zhang\u00a0W, Doherty\u00a0M (2015) Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score\u2014matched landmark analysis. Rheumatology 54:2145\u20132150","journal-title":"Rheumatology"},{"key":"1600_CR16","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.3899\/jrheum.141542","volume":"42","author":"J-H Chen","year":"2015","unstructured":"Chen\u00a0J\u2011H, Lan\u00a0J\u2011L, Cheng\u00a0C\u2011F, Liang\u00a0W\u2011M, Lin\u00a0H\u2011Y, Tsay\u00a0GJ, Yeh\u00a0W\u2011T, Pan\u00a0W\u2011H (2015) Effect of urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: a\u00a0case-matched cohort study. J\u00a0Rheumatol 42:1694\u20131701","journal-title":"J Rheumatol"},{"key":"1600_CR17","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1136\/annrheumdis-2014-205269","volume":"74","author":"M Dubreuil","year":"2015","unstructured":"Dubreuil\u00a0M, Zhu\u00a0Y, Zhang\u00a0Y, Seeger\u00a0JD, Lu\u00a0N, Rho\u00a0YH, Choi\u00a0HK (2015) Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis 74:1368\u20131372","journal-title":"Ann Rheum Dis"},{"key":"1600_CR18","doi-asserted-by":"publisher","first-page":"e99102","DOI":"10.1371\/journal.pone.0099102","volume":"9","author":"VC Kok","year":"2014","unstructured":"Kok\u00a0VC, Horng\u00a0J\u2011T, Chang\u00a0W\u2011S, Hong\u00a0Y\u2011F, Chang\u00a0T\u2011H (2014) Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a\u00a0population-based matched-cohort study. Plos One 9:e99102","journal-title":"Plos One"},{"key":"1600_CR19","first-page":"804","volume":"48","author":"AJ Luk","year":"2009","unstructured":"Luk\u00a0AJ, Levin\u00a0GP, Moore\u00a0EE, Zhou\u00a0X\u2011H, Kestenbaum\u00a0BR, Choi\u00a0HK (2009) Allopurinol and mortality in hyperuricaemic patients. Baillieres Clin Rheumatol 48:804\u2013806","journal-title":"Baillieres Clin Rheumatol"},{"key":"1600_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4078\/jrd.2023.0005","volume":"30","author":"YH Lee","year":"2023","unstructured":"Lee\u00a0YH, Song\u00a0GG (2023) Circulating leptin and its correlation with rheumatoid arthritis activity: a\u00a0meta-analysis. J\u00a0Rheum Dis 30:116\u2013125","journal-title":"J Rheum Dis"},{"key":"1600_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4078\/jrd.2023.0059","volume":"31","author":"P Waitayangkoon","year":"2024","unstructured":"Waitayangkoon\u00a0P, Leesutipornchai\u00a0T, Techasatian\u00a0W, Aiumtrakul\u00a0N, Tanariyakul\u00a0M, Arayangkool\u00a0C, Kanthajan\u00a0T, Nagamine\u00a0T, Kewcharoen\u00a0J (2024) Urate-lowering therapy is associated with a\u00a0reduced risk of arrhythmias: a\u00a0systematic review and meta-analysis. J\u00a0Rheum Dis 31:108\u2013115","journal-title":"J Rheum Dis"},{"key":"1600_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3904\/kjim.2016.195","volume":"33","author":"YH Lee","year":"2018","unstructured":"Lee\u00a0YH (2018) An overview of meta-analysis for clinicians. Korean J Intern Med 33:277","journal-title":"Korean J Intern Med"},{"key":"1600_CR23","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(05)63833-0","volume":"350","author":"DG Smith","year":"1997","unstructured":"Smith\u00a0DG, Egger\u00a0M (1997) Meta-analyses of randomised controlled trials. Lancet 350:1182","journal-title":"Lancet"},{"key":"1600_CR24","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins\u00a0JP, Thompson\u00a0SG (2002) Quantifying heterogeneity in a\u00a0meta-analysis. Stat Med 21:1539\u20131558","journal-title":"Stat Med"},{"key":"1600_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger\u00a0M, Smith\u00a0DG, Schneider\u00a0M, Minder\u00a0C (1997) Bias in meta-analysis detected by a\u00a0simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"1600_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jjcc.2012.01.013","volume":"59","author":"P Puddu","year":"2012","unstructured":"Puddu\u00a0P, Puddu\u00a0GM, Cravero\u00a0E, Vizioli\u00a0L, Muscari\u00a0A (2012) The relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: molecular mechanisms and clinical implications. J\u00a0Cardiol 59:235\u2013242","journal-title":"J Cardiol"},{"key":"1600_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4078\/jrd.2022.0001","volume":"30","author":"JK Ahn","year":"2023","unstructured":"Ahn\u00a0JK (2023) Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean. J\u00a0Rheum Dis 30:88\u201398","journal-title":"J Rheum Dis"},{"key":"1600_CR28","doi-asserted-by":"publisher","first-page":"582680","DOI":"10.3389\/fphar.2020.582680","volume":"11","author":"W Yu","year":"2020","unstructured":"Yu\u00a0W, Cheng\u00a0J\u2011D (2020) Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective. Front Pharmacol 11:582680","journal-title":"Front Pharmacol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01600-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T12:03:32Z","timestamp":1734523412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01600-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":28,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1600"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01600-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"30 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.H.\u00a0Lee and G.G.\u00a0Song declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case. Review and\/or approval by an ethics committee was not needed for this study because this research was a\u00a0meta-analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}